<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26233" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Opsonization</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thau</surname>
            <given-names>Lauren</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Asuka</surname>
            <given-names>Edinen</given-names>
          </name>
          <aff>All Saints University School of Medicine, Dominica.</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahajan</surname>
            <given-names>Kunal</given-names>
          </name>
          <aff>Holy Heart Advanced Cardiac Care Centre</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lauren Thau declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Edinen Asuka declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kunal Mahajan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26233.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Foreign invaders are continuously attacking the human&#x000a0;body.&#x000a0;Their attempts to hijack the body's machinery is quickly shut&#x000a0;down by the immune system. The immune system is a multilayered system that prevents the entry of pathogens into our body and allows us to live every day without constantly being sick. There are many mechanisms in which our immune system fights pathogens. One is opsonization. Opsonization is the process of recognizing and targeting invading particles for phagocytosis.<xref ref-type="bibr" rid="article-26233.r1">[1]</xref> This article will review 2 types of opsonins, complement C3b and antibodies, as well as the associated function, mechanisms, and the clinical significance of opsonization.</p>
      </sec>
      <sec id="article-26233.s2" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>The immune system is the body&#x02019;s defense against invaders. Opsonization&#x000a0;occurs in the immune system. The organ systems involved&#x000a0;are dependent&#x000a0;on&#x000a0;what mechanism is used. The lymphatic system&#x000a0;is responsible for&#x000a0;the transport and filtration of lymph fluid, which contains antibodies and lymphocytes. The cardiovascular system&#x000a0;is responsible for&#x000a0;the circulation of blood, which is necessary for an important factor in the alternative complement system pathway.&#x000a0;The lectin-complement system pathway requires the involvement of the liver. The liver is part of the gastrointestinal (GI) system. These organ systems work together to fight off bacteria, viruses, and other invaders that are trying to attack the body.</p>
      </sec>
      <sec id="article-26233.s3" sec-type="Function">
        <title>Function</title>
        <p>Opsonization is an immune process which uses opsonins to tag foreign pathogens for elimination by phagocytes.&#x000a0;Without an opsonin, such as an antibody, the negatively-charged cell walls of the pathogen and phagocyte repel each other. The pathogen can then avoid destruction and continue to replicate inside the human body.</p>
        <p>Opsonins are used&#x000a0;to overcome the repellent force between the negative cell walls and promote uptake&#x000a0;of&#x000a0;the pathogen by the macrophage. Opsonization&#x000a0;is an&#x000a0;antimicrobial technique to kill and stop the spread of disease.</p>
      </sec>
      <sec id="article-26233.s4" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>Opsonization of a pathogen can occur by antibodies or the complement system.</p>
        <p>
<bold>Antibodies</bold>
</p>
        <p>Antibodies are part of the adaptive immune system and are produced by plasma cells in response to a specific antigen. Different antigens stimulate different B cells to develop into plasma cells. An antibody&#x02019;s complex structure enables its specificity to certain antigens. At the end of the light and heavy chains, antibodies have variable regions, also known as antigen-binding sites. These sites allow the antibody to fit like &#x0201c;a lock and key&#x0201d; into the epitopes of specific antigens. Once the&#x000a0;antigen-binding&#x000a0;sites&#x000a0;are bound&#x000a0;to the epitopes on the antigen, the stem region of the antibody binds to the receptor on the phagocytes. Multiple antibodies bind to multiple sites on the antigen, increasing the chance and&#x000a0;efficiency&#x000a0;in which the pathogen&#x000a0;is engulfed&#x000a0;in the phagosome and destroyed by lysosomes. Immunoglobulin A (IgA) often exists in a monomeric state when in the bloodstream but it is secreted into the lumen of mucosal surfaces in a dimeric form. The dimeric form is joined together by a "J chain" with two antigen-binding sites for the neutralization of pathogens. IgA can be found in saliva, tears, respiratory, gastrointestinal, and genitourinary secretions. Immunoglobulin M (IgM), on the other hand, exists as a pentamer joined by a "J chain" when secreted into the bloodstream. Its response to pathogen invasion is mostly swift while that of Immunoglobulin G is delayed. When IgM is affixed on the surface of B cells, it exists as a monomer. Immunoglobulin G (IgG) is produced by plasma cells after class switching of antibodies. It can also cross the placenta and establish passive immunity.&#x000a0;Immunoglobulin D (IgD) is mainly found bound to B cells.&#x000a0;<xref ref-type="bibr" rid="article-26233.r2">[2]</xref>&#x000a0;Immunoglobulin E (IgE) activates mast cells and basophils leading to the release and formation of inflammatory mediators such as histamine, carboxypeptidase A3, tryptase, eosinophil chemotactic factor, prostaglandin D2, Leukotrienes, tumor necrosis factor-alpha, and platelet-activating factor (PAF). IgE is involved in allergic reactions and immune response to helminths and protozoan pathogens.&#x000a0;<xref ref-type="bibr" rid="article-26233.r3">[3]</xref></p>
        <p>
<bold>Complement System</bold>
</p>
        <p>The complement system is composed of over 30 proteins that improve the ability of antibodies and phagocytic cells to fight invading organisms. It initiates phagocytosis by opsonizing antigens. This system is also responsible for enhancing inflammation and cytolysis. However, in this article, we are going to focus on the complement systems role in Opsonization. The complement proteins, C1 through C9, are inactive when circulating throughout the human body. When a pathogen is detected, proteases cleave the inactive precursors rendering them active.<xref ref-type="bibr" rid="article-26233.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Classical pathway:</italic> The formation of the antigen-antibody complex triggers the classical pathway. The antigen-antibody reaction activates C1, which then cleaves inactive C4 to active C4a and C4b. C1 combines with C4b to form enzyme C14b. This enzyme is used to split C2 to C2a and C2b. C2a works together with enzyme C14b to form C14b2a. C14b2a, also known as C3 convertase, splits inactive C3 into active C3a and C3b.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Alternative pathway: </italic>The presence of lipid-carbohydrate complexes found in the cell wall of bacteria and fungus activates the alternative pathway. Factor C3, normally found in blood plasma, spontaneously hydrolyzes into C3b. The structure of C3b is more stable, increasing its reactivity. C3b reacts with Factor B, which is cleaved by Factor D into Ba and Bb. Then, Factor C3b and Bb come together to form C3bBb, also known as C3 convertase. C3 convertase splits inactive C3 into active C3a and C3b.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Lectin pathway:</italic> When a pathogen enters the human body, mannose-binding lectin (MBL) is released from the liver. It releases the lectin in response to the carbohydrates and mannose residues found in the pathogen&#x02019;s cell wall. This then activates MBL serine proteases MASP-1 and MASP-2. These proteases split inactive C4 and C2 into its active components: C4a, C4b, and C2a, C2b. Together, C4b and C2a form C3 convertase. C3 convertase splits inactive C3 into active C3a and C3b.</p>
          </list-item>
        </list>
        <p>Once created by one of the 3 pathways, C3b binds to multiple sites on the cell surface of the pathogen. It then binds to receptors on the surface of the macrophage or neutrophil. C3b is best known for its opsonizing activity because when it coats the microbe, phagocytosis activity is increased.</p>
      </sec>
      <sec id="article-26233.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of opsonization is when the process is not occurring. Opsonization fights off foreign invaders like bacteria and viruses and also supports self-tolerance and inhibits autoimmunity. Self-tolerance is the ability of the immune system to recognize its self-antigens without mounting a response. However, when opsonins are not available, or opsonization does not occur, apoptotic cell fragments remain in the body.<xref ref-type="bibr" rid="article-26233.r5">[5]</xref>&#x000a0;The three main complement components commonly implicated as anaphylatoxins include C3a, C4a, and C5a.&#x000a0;<xref ref-type="bibr" rid="article-26233.r6">[6]</xref>&#x000a0;CD55 also known as the Decay accelerating factor (DAF) helps to shield blood cells, particularly red blood cells from the complement system to prevent cell lysis. Defect in this protein can occur in certain diseases such as Paroxysmal nocturnal hemoglobinuria.&#x000a0;<xref ref-type="bibr" rid="article-26233.r7">[7]</xref>&#x000a0;Patients deficient in C3b tend to have recurrent respiratory and sinus tract infections. Deficiency of IgA predisposes the patient to respiratory and gastrointestinal tract infections like giardiasis. Patients with selective IgA deficiency are also at risk of a serious anaphylactic reaction if they receive blood products containing IgA.&#x000a0;<xref ref-type="bibr" rid="article-26233.r8">[8]</xref></p>
      </sec>
      <sec id="article-26233.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Many doctors and hospital staff aim to reduce the time a patient spends at a medical facility due to acquired infections. One of these acquired infections includes <italic toggle="yes">Staphylococcus epidermidis</italic>. <italic toggle="yes">S. epidermidis&#x000a0;</italic>can avoid phagocytosis by excreting polysaccharides. These polysaccharides prevent opsonins from recognizing the pathogen. <italic toggle="yes">S.&#x000a0;epidermidis&#x000a0;</italic>becomes increasingly resistant to antibiotics increasing the need to develop another approach to treat gram-positive and gram-negative infections. Artificial opsonin is a therapeutic strategy to enhance phagocytosis in immunocompromised patients and patients infected with antibiotic-resistant pathogens.<xref ref-type="bibr" rid="article-26233.r9">[9]</xref>&#x000a0;Artificial opsonins can help a variety of patients, such as patients who are immunosuppressed, patients allergic to the antibiotics, and lastly can help patients fight against antibiotic-resistant bacteria.</p>
        <p>Opsonophagocytosis killing assay (OPKA), is an in vitro assay commonly used in vaccine research. It can quantitatively measure antibody-mediated opsonophagocytosis. Researchers have used OPKA in studying various pathogens that have caused substantial deaths worldwide. For example, the researchers recently used it to study the efficiency of a vaccine against group A <italic toggle="yes">Streptococcus </italic>(GAS).<xref ref-type="bibr" rid="article-26233.r10">[10]</xref>&#x000a0;GAS has an M-protein virulence factor, which allows it to escape phagocytosis by the host. Scientists are developing an M-protein based vaccine which targets the production the M antibodies to decrease the survival of GAS. In recent years, GAS vaccine development has been delayed due to unreliable assays. However, OPKA is now being used because of its ability to limit variability. <xref ref-type="bibr" rid="article-26233.r10">[10]</xref>&#x000a0;OPKA can provide accurate and reproducible results and can advance vaccine development. Furthermore, the use of M antibodies as an opsonin is crucial for fighting group A <italic toggle="yes">Streptococcus</italic>.</p>
      </sec>
      <sec id="article-26233.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26233&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26233">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26233/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26233">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-26233.s8">
        <fig id="article-26233.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Opsonization Contributed by Lauren Thau</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Presentation1.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-26233.s9">
        <title>References</title>
        <ref id="article-26233.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mevorach</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Opsonization of apoptotic cells. Implications for uptake and autoimmunity.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2000</year>
            <volume>926</volume>
            <fpage>226</fpage>
            <page-range>226-35</page-range>
            <pub-id pub-id-type="pmid">11193038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26233.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoepel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Golebski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Drunen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>den Dunnen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Active control of mucosal tolerance and inflammation by human IgA and IgG antibodies.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>146</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-275</page-range>
            <pub-id pub-id-type="pmid">32387110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26233.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Silva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Halken</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Angier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arasi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arshad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Beyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>du Toit</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eigenmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grimshaw</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hoest</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khaleva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lack</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Szajewska</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Venter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Verhasselt</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>G</given-names>
              </name>
              <collab>European Academy of Allergy, Clinical Immunology Food Allergy, Anaphylaxis Guidelines Group</collab>
            </person-group>
            <article-title>Preventing food allergy in infancy and childhood: Systematic review of randomised controlled trials.</article-title>
            <source>Pediatr Allergy Immunol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>813</fpage>
            <page-range>813-826</page-range>
            <pub-id pub-id-type="pmid">32396244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26233.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuste</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Truedsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>J&#x000f6;nsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tay</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hyams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baxendale</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Goldblatt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Botto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway.</article-title>
            <source>Infect Immun</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>76</volume>
            <issue>8</issue>
            <fpage>3761</fpage>
            <page-range>3761-70</page-range>
            <pub-id pub-id-type="pmid">18541650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26233.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gershov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Brot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Elkon</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Opsonization of apoptotic cells and its effect on macrophage and T cell immune responses.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>987</volume>
            <fpage>68</fpage>
            <page-range>68-78</page-range>
            <pub-id pub-id-type="pmid">12727625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26233.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fei</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Qing-Kai-Ling Injection Induces Immediate Hypersensitivity Reaction <italic>via</italic> the Activation of Anaphylatoxin C3.</article-title>
            <source>Front Pharmacol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>1524</fpage>
            <pub-id pub-id-type="pmid">31998128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26233.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arcavi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ceballo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caracciolo</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Lazarowski</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Paroxysmal nocturnal hemoglobinuria: Test to monitor the action of eculizumab treatment.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>335</fpage>
            <page-range>335-340</page-range>
            <pub-id pub-id-type="pmid">32202389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26233.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grosserichter-Wagener</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Franco-Gallego</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmadi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moncada-V&#x000e9;lez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dalm</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Rojas</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Orrego</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Correa Vargas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hammarstr&#x000f6;m</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schreurs</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Dik</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>van Hagen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Boon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van Dongen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>van der Burg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pan-Hammarstr&#x000f6;m</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>van Zelm</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Defective formation of IgA memory B cells, Th1 and Th17 cells in symptomatic patients with selective IgA deficiency.</article-title>
            <source>Clin Transl Immunology</source>
            <year>2020</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>e1130</fpage>
            <pub-id pub-id-type="pmid">32355559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26233.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katzenmeyer</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Szott</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bryers</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Artificial opsonin enhances bacterial phagocytosis, oxidative burst and chemokine production by human neutrophils.</article-title>
            <source>Pathog Dis</source>
            <year>2017</year>
            <month>Aug</month>
            <day>31</day>
            <volume>75</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">28859309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26233.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moreland</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Zancolli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raynes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>JMS</given-names>
              </name>
              <name>
                <surname>Smeesters</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Sriskandan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carapetis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Goldblatt</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Development of an opsonophagocytic killing assay for group a streptococcus.</article-title>
            <source>Vaccine</source>
            <year>2018</year>
            <month>Jun</month>
            <day>18</day>
            <volume>36</volume>
            <issue>26</issue>
            <fpage>3756</fpage>
            <page-range>3756-3763</page-range>
            <pub-id pub-id-type="pmid">29776751</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
